Viral hepatitis: Europe needs to close the testing gap

July 27, 2020

Approximately four in five people living with hepatitis B and three out of four people with hepatitis C infection across the European Union and European Economic Area (EU/EEA) and the UK have not yet been diagnosed. This is a major obstacle on the way towards the Sustainable Development Goal (SDG) for health in 2030 as highlighted by ECDC on occasion of World Hepatitis Day.

ECDC is working in close collaboration with the World Health Organization to monitor the progress towards the elimination of hepatitis B (HBV) and C (HCV) across the EU/EEA. The first progress report highlights major gaps in prevention programmes in the region with suboptimal HBV vaccination coverage and insufficient levels of harm reduction targeting people who inject drugs.

The report shows that robust data for the so-called continuum of care looking at the numbers of diagnosed people and those in treatment and care are lacking in most countries. However, available data suggest that a high proportion of people living with hepatitis B and C infections appear to be undiagnosed and that many of those who have been diagnosed with hepatitis B and C infection are not receiving life-saving treatment. Available evidence also indicates that those at high risk of infection, including people who inject drugs and people in prison, are not being effectively targeted for testing.

In addition, mortality related to viral hepatitis is high across the region and there is very little evidence of progress towards the 2030 elimination target of a 65% reduction in mortality against the 2015 baseline.

"Looking at the latest monitoring results and surveillance data in 2020, we have to conclude that we are not on track to reach the 2030 target. To get there, Europe needs to massively scale up efforts to reduce the number of people who have never been tested for hepatitis B and C, especially among people at most risk of infection", highlights ECDC Director Andrea Ammon on occasion of World Hepatitis Day on 28 July. "Safe and effective vaccines are the main pillar for hepatitis B prevention. In addition, effective hepatitis treatment exists and improves the health of those who receive it. Treatment also helps preventing further transmission. It is as simple as that: people need to know their hepatitis status if we are to make progress towards eliminating these diseases by 2030."

European surveillance data show on-going transmission of hepatitis B and, despite a recent slight decline, high annual levels of hepatitis C diagnoses.

But according to recent ECDC findings, only a few countries across the EU/EEA have met the 2020 target of the European Action Plan to diagnose 50% of people with chronic hepatitis.

The ECDC testing guidance provides an overview of effective strategies to identify those with undiagnosed infection and highlights the importance of community testing and the integration of testing services (e.g. HIV and hepatitis) to enable synergies and efficiency in times of resource constraints.

Early diagnosis and linkage to care bring strong individual and public health benefits: effective viral hepatitis treatment either eliminates or suppresses the viruses significantly which in turn means that those on treatment interrupt existing transmission chains, preventing further infections.

The European Test Finder makes it easy to locate testing sites for HIV, hepatitis and sexually transmitted infections across Europe.
Read the full report

Monitoring the responses to hepatitis B and C epidemics in the EU/EEA Member States, 2019

Related content

Annual Epidemiological Report for 2018 - hepatitis B

Annual Epidemiological Report for 2018 - hepatitis C

Public health guidance on HIV, hepatitis B and C testing in the EU/EEA

Hepatitis B and C testing activities, needs, and priorities in the EU/EEA

Mortality from liver diseases attributable to hepatitis B and C in the EU/EEA - descriptive analysis and estimation of 2015 baseline

European Centre for Disease Prevention and Control (ECDC)

Related Hepatitis Articles from Brightsurf:

Busting Up the Infection Cycle of Hepatitis B
Researchers at the University of Delaware have gained new understanding of the virus that causes hepatitis B and the ''spiky ball'' that encloses its genetic blueprint.

Liver cancer: Awareness of hepatitis D must be raised
Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma.

Hepatitis B: New therapeutic approach may help to cure chronic hepatitis B infection
Researchers at Helmholtz Zentrum München, Technical University of Munich (TUM) and the German Center for Infection Research (DZIF) have developed a novel therapeutic approach to cure chronic hepatitis B.

Anti-hepatitis medicine surprises
A new effective treatment of hepatitis C not only combats the virus, but is also effective against potentially fatal complications such as reduced liver functioning and cirrhosis.

Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.

Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.

How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.

New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.

High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.

Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.

Read More: Hepatitis News and Hepatitis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to